PD2M Meet the Leader Forum

- Type: Archived Webinar
- Level: Intermediate
- Duration: 1 hour
- PDHs: 0.00
This webinar introduces established leaders within the pharmaceutical community to discuss their career journey, opportunities in the pharmaceutical industry, and future challenges and opportunities.
Moiz Diwan
Moiz Diwan is a director within the Process Research and Development organization at AbbVie. Moiz completed his M.S. and PhD degree from Purdue University in chemical engineering and bachelor’s degree from Indian Institute of Technology in chemical engineering. Moiz Joined Abbott/AbbVie in 2009 and was soon after assigned as a lead engineer on HCV 1st Gen Viekira API process development and led manufacturing process transfer to commercial facilities and supported regulatory submissions. After successful launch of Viekira, Moiz led cross functional API development team for HCV Next Gen....Read more
Carla Luciani
Dr. Luciani received her B.S in chemical engineering from Universidad Nacional de Mar del Plata in 2001 and PhD in chemical engineering from Universidad Nacional del Litoral in 2006. She spent 4 years at the University of Maryland, initially as a postdoctoral fellow and then as a research professor. She joined Small Molecule Design and Development at Eli Lilly in 2011 as a process engineer. In 2014, she joined the process design and development group as the leader of the drug substance M&S group. In that role, she guided a group of chemical engineers and developed models for hybrid and...Read more
Kevin Seibert
Kevin earned his BS, MS, and PhD in Chemical Engineering and has over 25 years’ experience working in small and ‘medium’ molecule syntheses for both Merck and Eli Lilly. Kevin was Area Head of Merck’s Natural Products Isolation pilot plant as well as technical lead at both Merck and Lilly in the engineering development organizations. He has worked on the process development and optimization of many early as well as late phase products and led the technology transfer, validation, and launch of several marketed compounds. Kevin has also led initiatives for developing enhanced filings in...Read more